Canaccord Genuity Reiterates a 'Buy' on RTI Biologics (RTIX) Following Presentation at AAOS Conference
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Price: $3.14 --0%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on RTI Biologics (NASDAQ: RTIX) price target of $6.50.
Analyst, William J. Plovanic, said, "We reiterate our rating on RTIX following its analyst presentation prior to the AAOS conference in San Francisco. Management highlighted its 2011 performance as well as reiterated its 2012 guidance while also providing incremental color into its key product development initiatives in F2012 and beyond. While we continue to believe the ongoing base business is strong, as evidenced by the F2011 full-year results, we note that medium-to-near-term development initiatives such as MAP3 (formerly MAPC) and porcine dermis, as well as long-term projects like Xenograft tendons, have the potential to be transformational."
For an analyst ratings summary and ratings history on RTI Biologics click here. For more ratings news on RTI Biologics click here.
Shares of RTI Biologics closed at $4.00 yesterday.
Analyst, William J. Plovanic, said, "We reiterate our rating on RTIX following its analyst presentation prior to the AAOS conference in San Francisco. Management highlighted its 2011 performance as well as reiterated its 2012 guidance while also providing incremental color into its key product development initiatives in F2012 and beyond. While we continue to believe the ongoing base business is strong, as evidenced by the F2011 full-year results, we note that medium-to-near-term development initiatives such as MAP3 (formerly MAPC) and porcine dermis, as well as long-term projects like Xenograft tendons, have the potential to be transformational."
For an analyst ratings summary and ratings history on RTI Biologics click here. For more ratings news on RTI Biologics click here.
Shares of RTI Biologics closed at $4.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lowe's (LOW) PT Lowered to $275 at Guggenheim
- Baird Starts Eaton Corporation (ETN) at Outperform
- Morgan Stanley Downgrades oOh!media (OML:AU) to Equalweight
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
